Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUOCINOLONE ACETONIDE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluocinolone acetonide is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cytokines (e.g., IL-1, IL-2, TNF-α). It also causes vasoconstriction and decreases cellular migration and immune response.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Atopic dermatitis,Seborrheic dermatitis,Psoriasis,Eczema,Lichen planus,Lichen simplex chronicus,Discoid lupus erythematosus,Otitis externa (otic solution),Corticosteroid-responsive dermatoses
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Topical: Apply thin film to affected area 2-4 times daily. Otic: 0.01% solution, 5 drops into ear canal twice daily. Intralesional: 3.3 mg/m L, 0.5-1 m L per injection every 1-2 weeks.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Terminal elimination half-life is approximately 1.3-1.5 hours following topical application; after systemic absorption (oral or injection), half-life is 1.5-2.0 hours, necessitating multiple daily dosing for sustained effect.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily hepatic via cytochrome P450 enzymes (CYP3A4) to inactive metabolites; also undergoes local metabolism in skin.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily hepatic metabolism with renal excretion of metabolites (approximately 80% renal, 20% biliary/fecal). Less than 1% excreted unchanged in urine.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Approximately 90% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.2-0.3 L/kg in adults; distributes extensively into tissues with higher concentrations in skin and synovial spaces after local administration.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Topical: very low systemic absorption (approximately 1-2% through intact skin, up to 10-20% through damaged skin or with occlusion); oral: 20-40% due to first-pass metabolism; intra-articular: nearly 100% locally with minimal systemic exposure.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No dose adjustment required for renal impairment as systemic absorption is minimal with topical use.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No dose adjustment required for hepatic impairment due to minimal systemic absorption.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Topical: Apply sparingly to affected area 2-3 times daily. Limit treatment duration to avoid systemic effects. Use lowest potency formulation; not recommended for prolonged use in children under 2 years.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Use with caution due to increased skin fragility and potential for systemic absorption. Apply sparingly and limit duration. Monitor for cutaneous adverse effects.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No FDA boxed warnings specific to fluocinolone acetonide; however, systemic absorption of topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
HPA axis suppression with prolonged use or application to large areas, occlusive dressings, or damaged skin.,Cushing's syndrome and hyperglycemia may occur with systemic absorption.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.,Local adverse reactions including burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Ophthalmic adverse effects: increased intraocular pressure, cataracts with periorbital use.,Not for ophthalmic use except as specifically indicated (e.g., otic solution).
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to fluocinolone acetonide or any component of the formulation,Untreated bacterial, fungal, viral (e.g., herpes simplex, vaccinia, varicella) or parasitic skin infections,Perioral dermatitis,Rosacea
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No known food interactions. No dietary restrictions required.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Topical corticosteroids are generally considered low risk in pregnancy. First trimester: No evidence of increased congenital malformations in human studies. Second and third trimesters: Risk of fetal growth restriction and low birth weight with prolonged or high-dose use. Systemic absorption may occur with extensive application, occlusive dressings, or prolonged use. Risk of adrenal suppression in neonate if used near term in high doses.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Excretion in breast milk is unlikely after topical application, but systemic absorption could occur with extensive use. The M/P ratio is unknown. Caution is advised: avoid application to the breast area before nursing, and use the lowest effective dose for the shortest duration.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dose adjustments required due to pharmacokinetic changes in pregnancy. Use the lowest effective potency and duration. Avoid excessive application, especially on large areas or under occlusive dressings.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Fluocinolone acetonide is a potent corticosteroid for dermatologic use. Avoid prolonged use on face, intertriginous areas, or under occlusion due to increased systemic absorption and risk of atrophy. For scalp psoriasis, the oil-based solution or shampoo forms may improve compliance. Use limited quantities in children to minimize HPA axis suppression. Discontinue if irritation or sensitization occurs.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Apply a thin layer only to affected skin areas, avoiding healthy skin.,Do not use on broken skin, open wounds, or infections unless directed.,Wash hands after application unless treating hands.,Avoid contact with eyes and mucous membranes.,Do not cover treated areas with bandages or wraps unless instructed by your doctor.,Do not use for more than 2 consecutive weeks without re-evaluation.,Inform your doctor if you are pregnant, breastfeeding, or have diabetes.,Report any signs of skin thinning, stretch marks, or worsening rash.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"The combination of flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID), and fluocinolone acetonide, a corticosteroid, may lead to an increased risk of gastrointestinal (GI) adverse effects, including ulceration and bleeding, due to additive inhibition of prostaglandin synthesis. Additionally, corticosteroids can mask the signs of infection and inflammation, potentially delaying diagnosis of NSAID-induced GI injury. Concomitant use also increases the risk of renal impairment, fluid retention, and electrolyte disturbances, particularly in patients with pre-existing renal dysfunction or heart failure."
"Combined use of fluocinolone acetonide (a topical corticosteroid) and fluoxymesterone (an anabolic androgen) increases the risk of sodium and water retention due to their synergistic mineralocorticoid effects. This can lead to exacerbation of hypertension, edema, and potentially precipitate congestive heart failure in susceptible patients. The effect is dose-dependent and more pronounced with systemic absorption of the topical steroid (e.g., when applied to large areas or broken skin)."
"Icatibant, a bradykinin B2 receptor antagonist used for hereditary angioedema, may theoretically attenuate the anti-inflammatory effects of fluocinolone acetonide, a corticosteroid. Corticosteroids suppress inflammation partly by inhibiting bradykinin production and signaling; blocking bradykinin receptors could paradoxically reduce corticosteroid efficacy. However, direct clinical evidence for this interaction is lacking, and the theoretical risk of decreased therapeutic response to fluocinolone acetonide when used with icatibant remains unconfirmed."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUOCINOLONE ACETONIDE vs ACTIQ, answered by our medical review team.
FLUOCINOLONE ACETONIDE is a Topical Corticosteroid that works by Fluocinolone acetonide is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cytokines (e.g., IL-1, IL-2, TNF-α). It also causes vasoconstriction and decreases cellular migration and immune response.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUOCINOLONE ACETONIDE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUOCINOLONE ACETONIDE is: Topical: Apply thin film to affected area 2-4 times daily. Otic: 0.01% solution, 5 drops into ear canal twice daily. Intralesional: 3.3 mg/m L, 0.5-1 m L per injection every 1-2 weeks.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUOCINOLONE ACETONIDE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUOCINOLONE ACETONIDE is classified as Category A/B. Topical corticosteroids are generally considered low risk in pregnancy. First trimester: No evidence of increased congenital malformations in human studies. Second and third trimes. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.